ArticleBlood advances2023
Real-world results of CAR T-cell therapy for large B-cell lymphoma with CNS involvement: a GLA/DRST study.
Article in Blood advances, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Safety and efficacy of CAR T-cell therapy in central nervous system lymphoma: a systematic review and meta-analysis.Frontiers in oncology · 2026Pooled it
- Efficacy and safety of third-generation CD19-CAR T cells incorporating CD28 and TLR2 intracellular domains for B-cell malignancies with central nervous system involvement: results of a pivotal trial.Journal of translational medicine · 2025Trial
- Trial
- Breakthroughs and challenges of CAR-T cell therapy in treating hematologic malignancies of the central nervous system.Blood science (Baltimore, Md.) · 2026Review
- Glofitamab crosses the blood-brain barrier and exhibits activity against primary and secondary CNS lymphoma.Blood advances · 2026Article
- Advances in CAR-T therapy for central nervous system lymphoma.Frontiers in immunology · 2026Review
- Put the CAR-T before the HRS: Advances in Anti-CD30 Immunotherapy Targeting Hodgkin/Reed-Sternberg Cells in Classical Hodgkin Lymphoma.Oncology research · 2026Review
- Sustained remission with PD-1 and BTK inhibitors maintenance after chimeric antigen receptor T-cell therapy in CNS lymphoma.Cancer immunology, immunotherapy : CII · 2025Article
- Tandem combination of ASCT and CAR T-cell therapy in highly refractory CNS lymphomas.British journal of haematology · 2025Article
- Preliminary evidence of CAR T-cell therapy activity in vitreoretinal lymphomas: An LOC network study.HemaSphere · 2025Article
- Outcomes of CD19 CAR-T therapy in central nervous system lymphoma: Insights from a multicentre experience.British journal of haematology · 2025Article
- Efficacy and safety of CAR T-cell therapy in patients with primary or secondary CNS lymphoma: A study on behalf of the EBMT and the GoCART coalition.HemaSphere · 2025Article
- CAR T-cell therapy response varies by extranodal disease site in large B-cell lymphoma.Blood cancer journal · 2025Article
- Anti-CD19 CAR T-cell therapy for primary and secondary CNS lymphomas.Bone marrow transplantation · 2025Review
- Current Issues and Future Perspectives of Targeted Therapies in Primary Mediastinal Large B-Cell Lymphoma.Journal of clinical medicine · 2025Review
- Low Rate of Central Nervous System Relapse of Diffuse Large B-Cell Lymphoma Despite Limited Use of Intrathecal Prophylaxis.Journal of hematology · 2025Article
- Comparison of efficacy and adverse effects of CD19/20 CART versus CD19 single-target CART in R/R DLBCL: a single-center retrospective study.Frontiers in immunology · 2025Article
- The contemporary spectrum of radiotherapy for hematologic malignancies involving the central nervous system: From focal therapy to craniospinal.Seminars in radiation oncology · 2025Review
- CAR-T Cells for the Treatment of Central Nervous System Tumours: Known and Emerging Neurotoxicities.Brain sciences · 2024Review
- Advances in CAR-T therapy for central nervous system tumors.Biomarker research · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.